Feed/Companies/SpliceBio

SpliceBio

As of 14 Oct 2026, SpliceBio has raised $135M across 1 verified round on record; latest: $135 million Series B led by EQT Life Sciences and Sanofi Ventures, announced 11 Jun 2025.

BUILT ON

Visit site

SpliceBio develops next-generation gene therapies using their proprietary Protein Splicing platform, targeting diseases caused by mutations in large genes.

splice.bioLinkedInBARCELONA, SPAIN

LATEST ROUND

Series B

$135M · 2025-06-11

RAISED ON RECORD · USD

$135M

across 1 verified round

INVESTORS

2 leads

SOURCES

from 2 publishers

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Series B

$135M · 2025-06-11

[ HISTORY ]

led by EQT Life Sciences, Sanofi Ventures

Round	Amount	Announced	Lead	Buzz
Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$135M	2025-06-11	EQT Life Sciences, Sanofi Ventures	No recent discussion
2 sources [ VERIFIED · CORRECTED ] read against 2 sources Sources agree on the Series B, amount, date, and syndicate. BioSpace describes SpliceBio as Barcelona-based, but no source explicitly states the headquarters city and country as a headquarters field.

SpliceBio

Company

Rounds

Sources

Profile

Investors

SpliceBio

Rounds

Profile

Sources

Series B$135M2025-06-112 sources

Investors

Series B$135M2025-06-119 investors